24 May 2013
Keywords: Merck & Co, Suvorexant, NDA filin, USA, FDA, Insomnia
Article | 07 February 2012
US drugs giant Merck & Co (NYSE: MRK) yesterday provided an update on the development program for suvorexant, the company's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 February 2012
© 2013 thepharmaletter.com